Mundipharma International Limited - Strategic SWOT Analysis
- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – GlobalData’s summarization of the company’s business strategy.
SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities – A list of key manufacturing facilities of the company.
Mundipharma International Limited (Mundipharma) is a biopharmaceutical company. It conducts research, develops, manufactures and commercializes drugs for pain management, cancer, rheumatoid arthritis and respiratory areas. The company offers these products in solid, semi-solid and liquid dosage forms. Mundipharma’s product portfolio includes fluticasone propionate / formoterol, indicated for the treatment of asthma; bendamustine, cytarabine and pralatrexate injection for the treatment of haematological malignancies; prednisone for the treatment of rheumatoid arthritis; and buprenorphine and hydromorphone for pain management. Mundipharma offers its products through its network of subsidiaries, independent associated companies, partners and joint ventures. It has operations in Europe, North America, Asia and Australia. Mundipharma is headquartered in Cambridge, the UK.
Mundipharma International Limited Key Recent Developments
Jan 26, 2015: Mundipharma Demonstrates Efficacy of BETADINE Formulations Against Ebola Virus Nov 02, 2013: New data presented by Mundipharma highlights a portfolio with cost efficient therapies Sep 10, 2013: Data show asthma exacerbation rates remain high, even among patients meeting criteria for current clinical control May 24, 2013: New research identifies link between sub-optimal asthma control across Europe and patient attitudes May 07, 2013: New survey reveals asthma continues to disrupt millions of lives across Europe
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.